Baseline Serum Cholesterol Is Associated with a Response to Pegylated Interferon Alfa-2b and Ribavirin Therapy for Chronic Hepatitis C Genotype 2

Table 3

Univariate and multivariate analysis of the factors associated with SVR to peginterferon alfa-2b and ribavirin therapy.

		Univariate analysis		Multivariate analysis
		𝑃	RR (95% CI)	𝑃	RR (95% CI)
Age	<57 years	0.646	1.24 (0.50–3.09)
Sex	Female	0.634	0.80 (0.33–1.97)
BMI	≥23 kg/m^2	0.221	1.86 (0.69–5.02)
Underlying liver disease
	CH	0.872	1.15 (0.21–6.32)
WBC	≥5100 /𝜇L	0.827	0.75 (0.37–2.22)
Hb	≥14.0 g/dL	0.317	0.62 (0.25–1.58)
Plt	≥20 × 10^4/𝜇L	0.112	2.10 (0.84–5.24)
AST	<40 IU/L	0.429	1.44 (0.58–3.55)
ALT	<52 IU/L	0.649	1.23 (0.50–3.02)
𝛾-GTP	<35 IU/L	0.525	0.75 (0.30–1.83)
TC	≥177 mg/dL	0.008	3.77 (1.41–10.05)	0.015	18.59 (1.78–193.65)
TG	≥88 mg/dL	0.101	2.60 (0.83–8.13)
LDL-C	≥98 mg/dL	0.028	4.91 (1.19–20.23)	0.800	1.25 (0.22–7.01)
Stage	F 3-4	0.419	0.60 (0.17–2.07)
Grade	A 2-3	0.809	1.13 (0.41–3.18)
HCV RNA
	<1000 KIU/mL	0.310	1.65 (0.63–4.31)

Relative risk (RR); 95% confidence interval (95% CI).